Citation
|
Abstract
|
2012
|
|
| Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins R, Masters C, Rowe C, Szoeke C, Taddei K, Ellis K and the AIBL research group. Predictors of rapid cognitive decline in Alzheimer’s disease: results from the Australian Imaging and Lifestyle (AIBL) study of ageing. International Psychogeriatrics 2012; 24: 197 – 204 [doi: 10.1017/S1041610211001335] |
|
| Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT, Ikonomovic MD, Ishii K, Jack CR, Jagust WJ, Johnson KA, Koeppe RA, Lowe VJ, Masters CL, Montine TJ, Morris JC, Nordberg A, Petersen RC, Reiman EM, Selkoe DJ, Sperling RA, Van Laere K, Weiner MW, Drzezga A. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012; 39:209-219. [doi: 10.1007/s00259-011-2045-0] |
|
| Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC and the AIBL Research Group. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 2012; 78: 477-484. [doi: 10.1212/WNL.0b013e318246d67a] |
|
| Lim YY, Ellis K, Harrington K, Ames D, Martins R, Masters C, Rowe C, Szoeke C, Darby D, Maruff P. Use of CogState brief battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. J ClinExpNeuropsychol 2012; 34: 345-58 |
|
| Barber B, Ames D, Ellis K, Martins R, Masters C, and Szoeke C. Lifestyle and late life cognitive health: sufficient evidence to act now?. International Psychogeriatrics 2012; 24: 683-8 [doi: 10.1017/s1041610211002912] |
|
| Chètelat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC, and the Australian Imaging Biomarker and Lifestyle study of Ageing (AIBL) Research Group. Relationships between memory performances and β-amyloid deposition at different stages of Alzheimer’s disease. Neurodegener Dis 2012; 10: 141-144 [doi: 10.1159/000334295] |
|
| Head R, Ames D, Masters CL, Rowe CC, Macaulay SL, and the Australian Imaging Biomarker and Lifestyle study of Ageing. The AIBL study throwing light on amyloid-beta and Alzheimer’s disease. Med J Aust 2012; 196: 376-377 |
|
| Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC. Comparison of (11)C-PiB and (18)F-florbetaben for A-beta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2012; 39: 983-9 [doi: 10.1007/s00259-012-2088-x] |
|
| Acosta O, Fripp J, Dore V, Bourgeat P, Favreau J-M, Chételat G, Rueda A, Villemagne VL, Szoeke C, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Bonner E, Gris F, Xiao D, Raniga P, Barra V, Salvado O. Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer’s disease. J Neurosci Methods 2012; 205: 96-109 [doi: 10.1016/j.jneumeth.2011.12.011] |
|
| Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, O’Keefe G, Jones G, Kung HF, Pontecorvo M, Masters CL, Skovronsky DM, Rowe CC. Differential diagnosis in Alzheimer’s disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. (In: Proceedings of the 10th International Conference on AD/PD 2011. Edited by Nitsch RM, Fisher A, Windisch M, Hanin I.) Neurodegen Dis 2012; 10: 161-165. |
|
| Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ. Variability in blood based amyloid beta assays: The need for consensus on pre-analytical processing. J Alzheimers Dis 2012; 30: 323-336 [doi: 10.3233/JAD-2012-120058] |
|
| Villain N, Chètelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL and the AIBL research group. Regional dynamics of amyloid-beta deposition in healthy elderly, Mild Cognitive Impairment and Alzheimer’s Disease: a voxelwisePiB-PET longitudinal study. Brain 2012; 135: 2126-2139 [doi: 10.1093/brain/aws125] |
|
| Lim YY, Harrington K, Ames D, Ellis KA, Lachovitzki R, Snyder PJ, Maruff P. Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer’s disease measured using the International Shopping List Test. J ClinExpNeuropsychol 2012 ; 34: 853 - 863[doi:10.1080/13803395.2012.689815] |
|
| Fodero-Travoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, Berndt M, McLean CA, Krause S, Rowe CC, Masters CL, Dyrks T, Cappai R. In Vitro characterisation of 18F-Florbetaben, an Aβ imaging radiotracer. Nucl Med Biol 2012; 39: 1042-1048 [doi: 10.1016/j.nucmedbio.2012.03.001] |
|
| Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P and the AIBL Research Group. Stronger effect of amyloid load than ApoE genotype on cognitive decline in healthy older adults. Neurology 2012; 79: 1645-1652 [doi: 10.1212/WNL.0b013e31826e9ae6] |
|
| Villemagne VL, Furumoto S, Fodero-Travoletti MT, Harada R, Mulligan RS, Kudo Y, Masters CL, Yanai K, Rowe CC, Okamura N. The challenges of tau imaging. Future Neurol 2012, 7(4):409-421 [doi: 10.2217/FNL.12.34] |
|
| Cyarto EV, Lautenschlager NT, Desmond PM, Ames D,Szoeke C, Salvado O, Sharman MJ, Ellis KA, Phal PM, Masters CL, Rowe CC, Martins RN and Cox KL. Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. Bio Med Central Psychiatry 2012; 12: 167.[doi:10.1186/1471-244X-12-167.] |
|
| Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam C-P, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, for the Alzheimers’s Disease Neuroimaging Initiative and the Australian Imaging Biomarker and Lifestyle research group. Blood-based protein biomarkers for diagnosis of Alzheimer’s disease.Arch Neurol. 2012; 69:1318-1325 [doi: 10.1001/archneurol.2012.1282][see also In Reply: Laske C. Blood-based biomarkers in Alzheimer’s disease: where are we now, where have we to go? and Laws SM, Doecke J, Martins RN. In reply:“Blood-based biomarkers in Alzheimer’s disease: where are we now, where have we to go?” – ChristophLaske. Arch Neurol (In Press, Oct 2012)]. |
|
2011
|
| Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan R, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assesment of Aβ and cognition in aging and Alzheimer’s disease. Ann Neurol 2011; 69: 181-192 [doi: 10.1002ana.22248] |
|
| Ellis KA, Rowe CC, Szoeke CEI, Villemagne VL, Ames D, Chételat G, Martins RN, Masters CL, Fripp J, Acosta O, Raniga P, Bourgeat PT, Salvado O. Advances in structural and molecular neuroimaging in Alzheimer’s disease. Med J Aust (Supplement) 2011; 194: 520-23. |
|
| Lim NK-H, Villemagne VL, Soon CPW, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li Q-X. Investigation of matrix metalloproteinases, MMP-2 and MMP-9 in plasma reveals a decrease of MMP-2 in Alzheimer’s disease. J Alzheimers Dis 2011 Jan 1; 26: 779-86. [doi: 10.3233/JAD-2011-101974] |
|
| Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C, Rowe CC, Szoeke C, Taddei K, Martins RN for the AIBL Research Group. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurol 2011; 76: 1091-1098. [doi: 10.1212/WNL.0b013e318211c352] |
|
| Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeke C, Ellis KA, and the AIBL research group. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement Geriatr Cogn Disord 2011; 31:173-178. [doi: 10.1159/000325171] |
|
| McBride SJ, Szoeke CEI, Good NM, Ames D, Martins RN, Masters CL, Maruff PT, Rowe CC, Savage G, Ellis KA and the AIBL Research Group. A web-based normative data tool for assessing cognitive performance in healthy older Australians. Med J Aust (Supplement) 2011; 194: 512-14. |
|
| Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, Ames D, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC and the Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group. Independent contribution of temporal Aβ deposition to memory decline in the predementia phase of Alzheimer’s disease. Brain 2011; 134: 798-807. [doi: 10.1093/brain/awq383] |
|
| Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O, Masters CL, Villemagne VL, Barnham KJ. Increasing the predictive accuracy of beta-amyloid blood-borne biomarkers in Alzheimer’s disease. J Alzheimers Dis 2011; 24: 47-59. [doi: 10.3233/JAD-2010-101722] |
|
| Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor A, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O’Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 2011; 134: 1089-1100. [doi: 10.1093/brain/awr038] |
|
| Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC. Cognition and beta-amyloid in preclinical Alzheimer’s disease: data from the AIBL study. Neuropsychologia 2011; 49: 2384-90 [doi: 10.1016/j.neuropsychologia.2011.04.012] |
|
| Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, Ackermann U, O’Keefe G, Jones G, Gong S, Tochon-Danguy H, Kung HF, Masters CL, Skovronsky D, Rowe CC. In vivo assessment of vesicular monoamine transporter type 2 in dementia with Lewy bodies and Alzheimer’s disease. Arch Neurol 2011; 68: 905-12 |
|
| Fodero-Tavoletti MT, Villemagne VL, Rowe CC, Masters CL, Barnham KJ, Cappai R. Amyloid-β: The seeds of darkness. Int. J. Biochem Cell Biol 2011; 43: 1247-51 |
|
| Mattsson N, Andreason U, Persson S, Arai H, Batish D, Bernardini S, Bocchio-Chiavetto L, Blankenstein RA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan A, Forlenza O, Frisoni G, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovitz AZ, Herukka S-K, Holtzman DM, Humpel C, Hyman B, Iqbal K, Jucker M, Kaeser S, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen C, Kummer M, Liu J, Lladó A, Lewczuk P, Li Q-X, Martins R, Masters CL, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine T, Nowatzke W, O’Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen R, Prvulovic D, de Reus HPM, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski J, Tumani H, Umek R, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek M, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer’s Association external quality control program for CSF biomarkers. Alzheimer’s and Dementia 2011; 7: 386 – 395 [doi: 10.1016/j.alz.2011.05.2243] |
|
| Yates PA, Sirisriro R, Villemagne VL, Farquason S, Masters CL, Rowe CC and the AIBL Research Group. Cerebral microhaemorrhage and brain Aβ amyloid in healthy ageing and Alzheimer’s disease. Neurol 2011; 77: 48 – 54 [doi: 10.1212/WNL.0b013e318221ad36] |
|
| Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O’Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC. Amyloid imaging with 18F-Florbetaben in Alzheimer’s disease and other dementias. J Nucl Med 2011 Aug; 52: 1210 – 1217 |
|
| Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins R, Masters C, Rowe C, Szoeke C, Taddei K, Ellis K and the AIBL research group. Predictors of rapid cognitive decline in Alzheimer’s disease: results from the Australian Imaging and Lifestyle (AIBL) study of ageing. International Psychogeriatrics 2011 July; 13: 1 – 8 |
|
| Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, Dumont J, Richard F, Cottel D, Berr C, Ames D, Masters, CL, Rowe CC, Szoeke C, Tzourio C, Dartigues JF, Buée L, Martins R, Amouyel P. Association of plasma Aβ peptides with blood pressure in the elderly. PLoS One 2011 April 15; 6 [doi: 10.1371/journal.pone.0018536] |
|
| Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A, Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T, Trounson BO, Villemagne VL, Ward V, Ames D, Masters CL, the AIBL Research Group, Bush AI. Homocysteine, vitamin B12 and folic acid levels in Alzheimer’s disease, mild cognitive impairment and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimers Dis 2011; 27: 909-22 |
|
| Acosta O, Fripp J, Dore V, Bourgeat P, Favreau J-M, Chételat G, Rueda A, Villemagne VL, Szoeke C, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Bonner E, Gris F, Xiao D, Raniga P, Barra V, Salvado O. Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer’s disease. J Neurosci Methods 2011; 205: 96-109 |
|
| Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T,Jack CR, Kaye J, Montine TJ, ParkDC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo M, Thies B, Morrson-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations of the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s and Dementia 2011; 7: 280-92 [doi: 10.1016/j.jalz.2011.03.003] |
|
2010
|
| Bourgeat P, Chételat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O on behalf of the AIBL Research Group. β-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-127. [doi: 10.1212/WNL.0b013e3181c918b5] |
|
| Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, Szoeke C, Ames D and the AIBL Research group. Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle Study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. Alzheimer’s & Dementia 2010; 6: 291-296. [doi: 10.1016/j.jalz.2010.03.009] |
|
| Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA, Faux NG, Masters CL, Barnham KJ. Blood borne amyloid-β dimer correlates with clinical markers of Alzheimer’s disease. J Neurosci 2010; 30: 6315-6322. [doi: 10.1523/JNEUROSCI.5180-09.2010] |
|
| Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, O’Keefe GJ, Salvado O, Masters CL, Rowe CC and the Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and β-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67: 317-324. [See also editorial: Rabinovici GD and Roberson ED. Beyond diagnosis: what biomarkers are teaching us about the “bio”logy of Alzheimer disease. Ann Neurol 2010; 67: 283-285.] [doi: 10/1002.ana.21955] |
|
| Villemagne VL, Pike K, Pejoska S, Boyd A, Power M, Jones G, Masters CL, Rowe CC. 11C-PiB PET ABri imaging in Worster-Drought syndrome (Familial British Dementia): A case report. J Alzheimers Dis. 2010; 19: 423-428. |
|
| Lui JK, Laws SM, Li Q-X, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN for the AIBL Research Group. Plasma amyloid-β as a biomarker in Alzheimer's Disease: The AIBL Study of Aging. J Alzheimers Dis 2010; 20; 1233-1242. |
|
| Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010: 31; 1275-1283. [doi: 10.1016/j.neurobiolaging.2010.04.007] |
|
| Chételat G, Villemagne VL, Pike KE, Baron J-C, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC and Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010; 133: 3349-3358. [doi: 10.10193/brain/awq187] |
|
| Rueda A, Acosta O, Couprie M, Bourgeat P, Fripp J, Dowson N, Romero E, Salvado O. Topology-corrected segmentation and local intensity estimates for improved partial volume classification of brain cortex in MRI. J Neurosci Methods 2010; 188: 305-315. [doi: 10.1016/j.jneumeth.2010.02.020] |
|
| Bahar-Fuchs A, Moss S, Pike KE, Villemagne VL, Masters CL, Rowe C, Savage G. Olfactory deficits and Aβ burden in AD, MCI and healthy ageing: a PiB PET Study. J Alzheimers Dis 2010; 22: 1081-1087. [doi: 10.3233/JAD-2010-100696] |
|
2009
|
| Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D and the AIBL Research Group. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics 2009; 21: 672-687. [doi: 10.1017/S1041610209009405] |
|
| Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, Connor AR, Masters CL, Rowe CC, Villemagne VL. Amyloid imaging in Alzheimer’s disease and other dementias. Brain ImagBehav 2009; 3: 246-261.[doi: 10.1007/s11682-009-9067-2] |
|
| Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li Q-X, Masters CL, Cappai R, Villemagne VL. Characterization of PiB binding to white matter in AD and other dementias. J Nucl Med 2009; 50: 198-204. [doi: 10.2967/jnumed.108.057984] |
|
| Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL.In vitro characterisation of BF227 binding to -synuclein/Lewy Bodies. Eur J Pharmacol 2009; 617: 54-58.[doi: 10.1016/j.ejphar.2009.06.042] |
|
| Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, Jones G, Baxendale D, Masters CL, Rowe CC, Collins SJ. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J NeurolNeurosurgPsychiatr 2009; 80: 998-1001. [doi: 10.1136/jnnp.2008.171496] |
|
| Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O’Keefe GJ, Masters CL, Mori H, Rowe CC. High striatal amyloid -peptide deposition across different autosomal Alzheimer’s disease mutation types. Arch Neurol 2009; 66: 1537-1544. [doi: 10.1001/archneurol.2009.285] |
|
| Okamura N, Fodero-Tavoletti MT, Kudo Y, Rowe CC, Furumoto S, Arai H, Masters CL, Yanai K, Villemagne VL. Advances in molecular imaging for the diagnosis of dementia. Expert Opin Med Diagn 2009; 3: 705-716. [doi: 10.1517/17530050903133790] |
|
| Acosta O, Bourgeat P, Fripp J, Zuluaga MA, Fripp J, Salvado O, Ourselin S. Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps. Medical Image Analysis 2009; 13: 730-743. [doi: 10.1016/j.media.2009.07.003] |
|
| Bates KA, Verdile G, Li Q-X, Ames D, Hudson P, Masters CL, Martins RN. Clearance mechanisms of Alzheimer’s amyloid-β peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009; 14: 469-486. [See also Erratum. Mol Psychiatry 2009; 14: 1144.] [doi: 10.1038/mp.2008.96] |
|
2008
|
|
| Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O’Keefe G, Masters CL, Ames D, Ellis K, Maruff P, Currie J, Villemagne VL, Rowe C, Salvado O and Ourselin S. Appearance modelling of C11 PiB PET images: characterizing amyloid deposition in Alzheimer’s disease, mild cognitive impairment and healthy aging. Neuroimage 2008; 43: 430-439 [doi: 10.1016/j.neuroimage.2008.07.053] |
|
| Bates KA, Verdile G, Li Q-X, Ames D, Hudson P, Masters CL and Martins RN. Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2008; 14: 469-486 [doi: 10.1038/mp.2008.96] |
|
| Fripp J, Bourgeat P, Villemagne VL, Acosta O, Chetelat G, Jones G, O’Keefe G, Masters CL, Ames D, Martins RN, Ellis K, Szoeke C, Ourselin S, Rowe CC, Salvado O. MR-less approach for the analysis of 11C PiB PET images: population of elderly, mild cognitive impaired and Alzheimer disease subjects. Med Image Comput Comput Assist Interv 2008; 11: 442-449 |
|
| Raniga P, Bourgeat P, Fripp J, Acosta O, Villemagne V, Rowe C, Masters C, Jones G, O’Keefe G, Salvado O, Ourselin S. Automated 11C-PiB standardized uptake value ratio. Academic Radiology 2008; 15: 1376-1389. |
|
| Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis KA, Maruff P, Currie J, Villemagne VL, Rowe CC, Salvado O, Ourselin S. Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. NeuroImage 2008; 43: 430-439. |
|
| Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Luhman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008; 7: 129-135. |
|
| Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC. The ART of loss: Aβ imaging in the evaluation of Alzheimer’s disease and other dementias. Mol Neurobiol 2008; 38: 1-15. |
|
| Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O’Keefe G, Någren K, Chaudhury KR, Masters CL, Brooks DJ. Amyloid load in Parkinson’s disease dementia and Lewy Body dementia measured with [11C]PIB-positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331-1338. |
|
| Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O’Keefe GO, Masters CL, Rowe CC. Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease. Neuropsychologia 2008; 46: 1688-1697. |
|
| Weaver Cargin J, Collie A, Masters C, Maruff P. The nature of cognitive complaints in healthy older adults with and without objective memory decline. J Clin Exp Neuropsychol 2008; 30: 245-257. |
|
Publications